1-Hexyl-piperidine-4-carboxamide | 199856-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Hexyl-piperidine-4-carboxamide
• 英文别名: 1-Hexylpiperidine-4-carboxamide
• CAS: 199856-06-9
• 化学式: C₁₂H₂₄N₂O
• mdl: MFCD00086250
• 分子量: 212.335
• InChiKey: HCWWBSHYGXWMJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Hexyl-piperidine-4-carboxamide 在 lithium aluminium tetrahydride 、 1-羟基苯并三唑 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-amino-5-chloro-N-[(1-hexyl-4-piperidinyl)methyl]-2-methoxybenzamide
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists

  摘要：

  A number of new carboxamide derivatives were synthesized. The affinity of these compounds for the serotoninergic 5-HT4 receptor was evaluated by use of radioligand-binding techniques. The agonistic activity was evaluated as the contractile effect of the ascending colon isolated from guinea-pigs. Among these compounds, 4-amino-5-chloro-2-methoxy-N-[1-[2-[(methylsulfonyl)amino]ethly]-4-piperidinylmethyl]benzamide (24) showed a high affinity for the 5-HT4 receptor (Ki = 9.6 nM). Compound 24 displayed a higher affinity for 5-HT4 receptors than the other receptors, including, 5-HT3 and dopamine D-2 receptors. In addition, compound 24 was confirmed to be a potent 5-HT4 receptor agonist (ED50 - 7.0 nM). An interaction model between compound 24 and 5-HT4 receptor was proposed. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80083-x
• 作为产物：
  描述：

  1-碘己烷 在 potassium carbonate 作用下， 生成 1-Hexyl-piperidine-4-carboxamide
  参考文献：
  名称：

  Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists

  摘要：

  这项发明提供了具有结构式1的化合物，其中A、B、Z、R和R1如前文所定义，或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。

  公开号：

  US20020037907A1

文献信息

• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• 4-Substituted piperidine derivatives
  申请人：McKerracher Lisa

  公开号：US20050272751A1

  公开（公告）日：2005-12-08

  Substituted piperidine compounds represented by the structure I are provided, wherein each of R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g , R 1h , R 2 , R 2A , R 3 , R 4 , A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构式I表示的取代哌啶化合物，其中R1a、R1b、R1c、R1d、R1e、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n的定义如规范中所述。结构式I的取代哌啶化合物可以渗透或穿过神经细胞膜进入神经细胞内部，可以抑制哺乳动物神经细胞中发现的细胞内Rho激酶酶，并可用于修复哺乳动物中心和周围神经系统中的受损神经。这些化合物可以诱导哺乳动物神经细胞的轴突再生或生长，从而诱导受损或患病的神经组织再生。这些化合物还可作为Rho激酶酶拮抗剂，在治疗涉及Rho激酶酶的疾病状态中发现其他用途。含有这些取代哌啶化合物的制药组合物可用于促进神经轴突生长，并用于治疗需要Rho激酶抑制的疾病。
• Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine &bgr;-3 adrenergic receptor agonists
  申请人：Wyeth

  公开号：US06506901B2

  公开（公告）日：2003-01-14

  This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供具有式I的化合物，其结构中A、B、Z、R和R1如前所定义，或其药学上可接受的盐，这些化合物在治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖耐受性不良有关）、动脉粥样硬化、胃肠道疾病、神经遗传性炎症、青光眼、眼压增高和频繁排尿方面非常有用；并且在治疗或抑制II型糖尿病方面特别有用。
• 4-SUBSTITUTED PIPERIDINE DERIVATIVES
  申请人：Bioaxone Therapeutique Inc.

  公开号：EP1720874A1

  公开（公告）日：2006-11-15
• US6506901B2
  申请人：——

  公开号：US6506901B2

  公开（公告）日：2003-01-14